Clinical Trial Update: Provide Initial Evidence of Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy to Support the Pivotal CT-P10 Therapeutic Equivalence Trial [Phase 1]

View source ↗

Summary

This report provides Phase 1 safety, pharmacokinetics/pharmacodynamics, and preliminary efficacy data for CT-P10 (rituximab biosimilar) in diffuse large B-cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CT-P10 (rituximab biosimilar)

Snippet

Sponsor: Celltrion | Conditions: Diffuse Large B-Cell Lymphoma | Phase 1 | Status: TERMINATED